Rafael T de Sousa1, Marcus V Zanetti2, Geraldo F Busatto3, Margaret G Mouro4, Carlos A Zarate5, Wagner F Gattaz6, Elisa M Higa5, Rodrigo Machado-Vieira7. 1. Laboratory of Neuroscience, LIM-27, Department and Institute of Psychiatry, University of Sao Paulo, Brazil. 2. Laboratory of Neuroscience, LIM-27, Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Brazil; Laboratory of Psychiatric Neuroimaging, LIM-21, Department and Institute of Psychiatry, University of Sao Paulo, Brazil. 3. Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Brazil; Laboratory of Psychiatric Neuroimaging, LIM-21, Department and Institute of Psychiatry, University of Sao Paulo, Brazil. 4. Department of Medicine, Nephrology Division, UNIFESP/Escola Paulista de Medicina, Sao Paulo, Brazil. 5. Experimental Therapeutics and Pathophysiology Branch (ETPB), National Institute of Mental Health, NIH, Bethesda, MD, USA. 6. Laboratory of Neuroscience, LIM-27, Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Brazil. 7. Laboratory of Neuroscience, LIM-27, Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of Sao Paulo, Brazil; Experimental Therapeutics and Pathophysiology Branch (ETPB), National Institute of Mental Health, NIH, Bethesda, MD, USA. Electronic address: machadovieirar@gmail.com.
Abstract
BACKGROUND: Altered nitric oxide (NO) signaling has been associated with the pathophysiology of Bipolar Disorder (BD), directly affecting neurotransmitter release and synaptic plasticity cascades. Lithium has shown to regulate NO levels in preclinical models. However, no study has addressed peripheral NO levels in unmedicated BD. Also, lithium's effects on NO levels have not been studied in humans. METHODS: Plasma NO was evaluated in subjects with BD I and II during a depressive episode (n = 26). Subjects had a score of ≥18 in the 21-item Hamilton Depression Rating Scale and were followed-up during a 6-week trial with lithium. Plasma NO levels were also compared to matched healthy controls (n = 28). NO was determined by chemiluminescence method. RESULTS: Lithium treatment significantly increased plasma NO levels after 6 weeks of treatment in comparison to baseline levels in bipolar depression (p = 0.016). Baseline NO levels during depressive episodes showed no difference when matching up to healthy controls (p = 0.66). CONCLUSION: The present findings suggest that lithium upregulates NO signaling in unmedicated BD with short illness duration. Further studies with larger samples are needed to confirm the effects of lithium on NO pathway and its association with synaptic plasticity and therapeutics of BD. Published by Elsevier Ltd.
BACKGROUND: Altered nitric oxide (NO) signaling has been associated with the pathophysiology of Bipolar Disorder (BD), directly affecting neurotransmitter release and synaptic plasticity cascades. Lithium has shown to regulate NO levels in preclinical models. However, no study has addressed peripheral NO levels in unmedicated BD. Also, lithium's effects on NO levels have not been studied in humans. METHODS: Plasma NO was evaluated in subjects with BD I and II during a depressive episode (n = 26). Subjects had a score of ≥18 in the 21-item Hamilton Depression Rating Scale and were followed-up during a 6-week trial with lithium. Plasma NO levels were also compared to matched healthy controls (n = 28). NO was determined by chemiluminescence method. RESULTS:Lithium treatment significantly increased plasma NO levels after 6 weeks of treatment in comparison to baseline levels in bipolar depression (p = 0.016). Baseline NO levels during depressive episodes showed no difference when matching up to healthy controls (p = 0.66). CONCLUSION: The present findings suggest that lithium upregulates NO signaling in unmedicated BD with short illness duration. Further studies with larger samples are needed to confirm the effects of lithium on NO pathway and its association with synaptic plasticity and therapeutics of BD. Published by Elsevier Ltd.
Authors: H-G Bernstein; A Heinemann; D Krell; C Mawrin; H Bielau; P Danos; S Diekmann; G Keilhoff; B Bogerts; B Baumann Journal: Ann N Y Acad Sci Date: 2002-11 Impact factor: 5.691
Authors: K Rejdak; A Petzold; M A Sharpe; M Smith; G Keir; Z Stelmasiak; E J Thompson; G Giovannoni Journal: J Neurol Sci Date: 2003-04-15 Impact factor: 3.181
Authors: Fábio B Mury; Weber C da Silva; Nádia R Barbosa; Camila T Mendes; Juliana S Bonini; Jorge Eduardo Souza Sarkis; Martin Cammarota; Ivan Izquierdo; Wagner F Gattaz; Emmanuel Dias-Neto Journal: Eur Arch Psychiatry Clin Neurosci Date: 2015-12-11 Impact factor: 5.270
Authors: Mehmet F Ustundag; Halil Ozcan; Ali G Gencer; Enver D Yilmaz; Kerim Uğur; Elif Oral; Mustafa Bilici Journal: Saudi Med J Date: 2020-01 Impact factor: 1.484